NCT03760848View on ClinicalTrials.gov

Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

February 2, 2019

Study Completion Date

February 2, 2019

Conditions
Healthy
Interventions
DRUG

Aramchol

Aramchol 600 mg

DRUG

Midazolam

Midazolam 2 mg

DRUG

Atorvastatin

atorvastatin 40 mg

Trial Locations (1)

NW10 7EW

Hammersmith Medicines Research (HMR), London

Sponsors
All Listed Sponsors
collaborator

Hammersmith Medicines Research

OTHER

collaborator

Analyst Research Laboratories

OTHER

collaborator

Alderley Analytical Ltd.

INDUSTRY

collaborator

Diamond Pharma Services Regulatory Affairs Consultancy

OTHER

lead

Galmed Pharmaceuticals Ltd

INDUSTRY